Fortress Biotech has established nine subsidiary companies since 2013, each financed differently and each focused on an area of unmet need. Fortress CEO and longtime life sciences investor Lindsay Rosenwald lays out his ambitious plans for the future.

A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.

India's biggest contract research firm Jubilant Life Sciences says it has joined forces with the German arm of France's biggest pharma firm Sanofi to discover new therapies for treating metabolic disorders.

Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.